BNTX:NASDAQ
BioNTech SE - ADR
95,73 US$
arrow_downward
-1,96%(-1,91) 1D
96,50 US$
arrow_upward
+0,80% (+0,77)bedtimeJashtë orarit
Mbyllur: 6 tet, 4:00:01 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BNTX...
Hap
99,49 US$
I lartë
100,02 US$
I ulët
95,31 US$
Kapitalizimi i tregut
23,87 mld
Vëllimi mesatar
1,04 mln
Vëllimi
899,39 mijë
Maksimumi 52-javor
123,98 US$
Minimumi 52-javor
79,52 US$
Fitimet për aksion
-7,53 US$
Beta
1,22
Aksionet në qarkullim
251,20 mln
Numri i punonjësve
8 mijë
Hap
99,49 US$
I lartë
100,02 US$
I ulët
95,31 US$
Kapitalizimi i tregut
23,87 mld
Vëllimi mesatar
1,04 mln
Vëllimi
899,39 mijë
Maksimumi 52-javor
123,98 US$
Minimumi 52-javor
79,52 US$
Fitimet për aksion
-7,53 US$
Beta
1,22
Aksionet në qarkullim
251,20 mln
Numri i punonjësve
8 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
AD HOC NEWS
·
5 orë më parë
BioNTech stock fell 1.96 percent despite a Buy consensus
AD HOC NEWS
·
15 orë më parë
Morgan Stanley sets a Buy rating for BioNTech stock
Yahoo Finance
·
1 ditë më parë
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
AD HOC NEWS
·
1 ditë më parë
BioNTech stock draws Moderate Buy consensus at USD 126 target
Profili
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Rreth BioNTech SE - ADR